Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.61 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491221 | 0.80 | GSK3B (0.60) | GSK3BDYRK1AALDH1A1 | |
| SCHEMBL1395948 | 0.78 | GSK3B (0.55) | GSK3BNOTUMDYRK1ANPC1MAPT | |
| SCHEMBL22471887 | 0.78 | DYRK1A (0.61) | GSK3BNOTUMDYRK1ANPC1MAPT | |
| SCHEMBL13435542 | 0.77 | NPC1 (0.62) | GSK3BDYRK1AALDH1A1LMNANPC1 | |
| SCHEMBL3492535 | 0.76 | GSK3B (1.00) | GSK3BNPC1MAPTRAB9A | |
| SCHEMBL3490039 | 0.76 | GSK3B (0.66) | GSK3BDYRK1A | |
| SCHEMBL3493961 | 0.75 | GSK3B (0.68) | GSK3BDYRK1ANPC1MAPTRAB9A | |
| SCHEMBL3492383 | 0.75 | GSK3B (0.68) | GSK3BALDH1A1LMNANPC1MAPT | |
| SCHEMBL3493802 | 0.75 | GSK3B (0.54) | GSK3BALDH1A1NPC1RAB9A | |
| SCHEMBL3491254 | 0.75 | GSK3B (1.00) | GSK3BNPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492378-B2 | GSK-3β inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20100069381-A1 | GSK-3BETAINHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069381-A1 | GSK-3BETAINHIBITOR | GSK3B, GSK3A, GSKIP | GSK3B 1/4885NOTUM 992/4885DYRK1A 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.